CA3167166A1 - Smarca2-vhl degraders - Google Patents

Smarca2-vhl degraders

Info

Publication number
CA3167166A1
CA3167166A1 CA3167166A CA3167166A CA3167166A1 CA 3167166 A1 CA3167166 A1 CA 3167166A1 CA 3167166 A CA3167166 A CA 3167166A CA 3167166 A CA3167166 A CA 3167166A CA 3167166 A1 CA3167166 A1 CA 3167166A1
Authority
CA
Canada
Prior art keywords
compound
mmol
carcinomas
amino
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3167166A
Other languages
English (en)
French (fr)
Inventor
Abhisek Banerjee
Victor J. Cee
Ning Chen
Xiaofen Li
Ryan Paul Wurz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA3167166A1 publication Critical patent/CA3167166A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3167166A 2020-01-10 2021-01-08 Smarca2-vhl degraders Pending CA3167166A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959502P 2020-01-10 2020-01-10
US62/959,502 2020-01-10
PCT/US2021/012683 WO2021142247A1 (en) 2020-01-10 2021-01-08 Smarca2-vhl degraders

Publications (1)

Publication Number Publication Date
CA3167166A1 true CA3167166A1 (en) 2021-07-15

Family

ID=74495106

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3167166A Pending CA3167166A1 (en) 2020-01-10 2021-01-08 Smarca2-vhl degraders

Country Status (7)

Country Link
US (1) US20230091042A1 (https=)
EP (1) EP4087658A1 (https=)
JP (1) JP7706456B2 (https=)
AU (1) AU2021205326A1 (https=)
CA (1) CA3167166A1 (https=)
MX (1) MX2022008487A (https=)
WO (1) WO2021142247A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
WO2022029617A1 (en) * 2020-08-04 2022-02-10 Aurigene Discovery Technologies Limited 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
EP4259144A4 (en) * 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
US11993599B2 (en) 2021-08-09 2024-05-28 Genentech, Inc. Therapeutic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519152B2 (en) * 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
US20190300521A1 (en) * 2018-04-01 2019-10-03 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
US12371426B2 (en) * 2018-04-26 2025-07-29 Aurigene Discovery Technologies Limited Pyridazine derivatives as SMARCA2/4 degraders
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)

Also Published As

Publication number Publication date
MX2022008487A (es) 2022-08-02
US20230091042A1 (en) 2023-03-23
EP4087658A1 (en) 2022-11-16
AU2021205326A1 (en) 2022-07-21
WO2021142247A1 (en) 2021-07-15
JP2023510746A (ja) 2023-03-15
JP7706456B2 (ja) 2025-07-11

Similar Documents

Publication Publication Date Title
CA3167166A1 (en) Smarca2-vhl degraders
JP6388991B2 (ja) キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド
JP6163205B2 (ja) 補体経路モジュレーターおよびその使用
US11572374B2 (en) N-cyano-7-azanorbornane derivatives and uses thereof
CN102834382B (zh) 作为钙释放激活钙通道调节剂的吡唑衍生物
AU2019264253B2 (en) Factor XIIa inhibitors
CN112262134A (zh) 小脑蛋白配体和包括其的双官能化合物
CN108137507A (zh) 基于mdm2的蛋白水解调节剂和相关的使用方法
JP6500024B2 (ja) Ｌｔａ４ｈ阻害剤としてのヘテロアリールブタン酸誘導体
IL322853A (en) History of 1-(([1,1'-biphenyl]-2-yl)sulfonyl)-4-fluoro-n-(3-(methylsulfonyl)allyl)piperidine-4-carboxamide as ras-pi3k modulators for exemplary cancer therapy
SG182400A1 (en) Voltage-gated sodium channel blockers
CZ301631B6 (cs) Ortho- a meta-substituované bisarylové slouceniny a farmaceutické prostredky, které je obsahují
MXPA03011336A (es) Inhibidores de proteasa del virus de inmunodeficiencia humana (vih), composiciones que los contienen, sus usos farmaceuticos y materiales para su sintesis.
CN104640843A (zh) 1-(环烷基羰基)脯氨酸衍生物
CN106928198B (zh) 磺酰胺衍生物及其制备方法与应用
AU2014274354A1 (en) Dihydropyridinone MGAT2 inhibitors
US20240374738A1 (en) Bifunctional compound capable of degrading receptor tyrosine kinase and application thereof
EP4395828A1 (en) Bifunctional degraders comprising a tead binder
AU2012279091A1 (en) Voltage-gated sodium channel blockers
JP2023552655A (ja) ボロン酸化合物
TW202342060A (zh) Ｌｏｎｐ１抑制劑化合物、用途及方法
CA3214936A1 (en) Arylacetyl inhibitors of tg2 and uses thereof
NZ717556B2 (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241219

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241219

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241219

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241219

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250109

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250109

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250428

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250729

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250729

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251217